Clinical Approach for Platinum-Sensitive Recurrent Ovarian Cancer
Platinum-Sensitive Recurrent Ovarian Cancer
September 2014
November 2016
January 2018
KEYNOTE-A18 Supports Pembrolizumab and CRT as New Standard in High-Risk Cervical Cancer
September 14th 2024Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced cervical cancer.
Read More
Pembrolizumab Plus CCRT Scores in East Asian Subgroup With Cervical Cancer
September 9th 2024Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Read More